29:
131:
483:
219:). According to the company web site as of November 2016 studies on the drug are no longer accepting new patients, but Clovis would continue to supply the drug to patients whose physicians had recommended continued treatment.
173:
with several products in its product pipeline. As of
December 31, 2017, the company was not profitable and had incurred losses in each year since its inception in April 2009. In December 2022, Clovis Oncology filed for
732:
Balasubramaniam, Sanjeeve; Beaver, Julia A.; Horton, Sara; Fernandes, Laura L.; Tang, Shenghui; Horne, Hisani N.; Liu, Jinzhong; Liu, Chao; Schrieber, Sarah J.; Yu, Jingyu; Song, Pengfei (December 1, 2017).
886:
475:
505:
881:
563:
654:
436:
621:
680:
223:
808:
706:
312:
593:
515:
538:
406:
836:"Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors"
735:"FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer"
215:. A phase III trial was completed in April 2016 and had it been approved it would have competed with AstraZeneca's Tagrisso (
783:
571:
246:
262:
450:
250:
212:
170:
71:
269:". In 2023, rucaparib was sold to Pharmaand GmbH (Pharma&) as part of Clovis's bankruptcy proceedings.
154:
175:
812:
710:
222:
In
September 2018, the company and two former executives agreed to a $ 20 million settlement with the
61:
857:
764:
756:
258:
187:
162:
93:
847:
746:
451:"Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286"
414:
194:
stone tools dated to 11,000 BCE, discovered in the front yard of
Mahaffy's home in Boulder.
622:
Investors doubt efficacy of Clovis lung cancer med rociletinib, shares off 11%. April 2016
506:"A Festivus for the Invest in Us -- It's Time for the Airing of Grievances | Fox Business"
281:
266:
242:
238:
191:
39:
875:
254:
57:
47:
28:
510:
381:
751:
734:
356:
338:
216:
208:
226:
on claims it exaggerated to investors the efficacy of Roci in patient trials.
760:
852:
835:
277:
265:)-associated advanced ovarian cancer who have been treated with two or more
234:
861:
768:
633:
594:"FDA Requests Additional Data for Rociletinib in EGFR T790M-Mutant NSCLC"
253:
for the use of rucaparib "for the treatment of patients with deleterious
158:
97:
784:"Navigating bankruptcy, Clovis reaches deal to sell cancer drug Rubraca"
564:"Clovis Oncology Announces Regulatory Update for Rociletinib NDA Filing"
190:. The company was named in honor of the Mahaffy cache, a collection of
539:"Clovis Oncology stock bludgeoned after delay in cancer drug approval"
681:"Clovis, CEO, Ex-CFO Agree to Pay $ 20M+ to Settle SEC Charges | GEN"
166:
53:
655:"Clovis Oncology, execs to pay $ 20 million to settle SEC charges"
289:
285:
476:"13,000-year-old stone tool cache set for exhibit at CU-Boulder"
292:
and has undergone clinical trials for advanced solid tumors.
186:
Clovis
Oncology was founded in 2009 by Patrick Mahaffy in
407:"Clovis Oncology – Products & Companion Diagnostics"
887:
Companies that filed for
Chapter 11 bankruptcy in 2022
313:"Clovis Oncology: A Winning Or Losing Lottery Ticket?"
161:. Clovis was founded in 2009 and is headquartered in
138:
125:
111:
103:
77:
67:
45:
35:
241:in Phase II and III clinical trials for advanced
157:which mainly markets products for treatment in
165:. The company is a publicly traded company on
882:Pharmaceutical companies of the United States
8:
439:for the fiscal year ended December 31, 2017.
21:
20:
851:
750:
617:
615:
307:
305:
301:
537:Wallace, Alicia (November 16, 2015).
7:
449:Singh, Vandana (December 12, 2022).
169:under the symbol CLVS and is in the
486:from the original on July 22, 2021
224:Securities and Exchange Commission
14:
130:
129:
27:
514:. March 7, 2016. Archived from
413:. March 9, 2015. Archived from
16:American pharmaceutical company
1:
782:Bell, Jacob (April 7, 2023).
752:10.1158/1078-0432.CCR-17-1337
284:. It is also an inhibitor of
247:Food and Drug Administration
834:Soria; et al. (2014).
207:The company was developing
83:; 15 years ago
903:
213:non-small cell lung cancer
171:NASDAQ Biotechnology Index
26:
739:Clinical Cancer Research
480:The Chaffee County Times
245:. In December 2016, the
435:Clovis Oncology, Inc.
155:pharmaceutical company
62:Russell 2000 Component
853:10.1093/annonc/mdu390
809:"Lucitanib at Clovis"
707:"Rucaparib at Clovis"
357:"Clovis Oncology Inc"
211:, as a treatment for
176:Chapter 11 bankruptcy
687:. September 19, 2018
661:. September 18, 2018
251:accelerated approval
600:. November 16, 2015
482:. October 9, 2015.
361:www.marketwatch.com
319:. November 16, 2015
198:Product development
140:Number of employees
134:$ 165 Million(2020)
23:
840:Annals of Oncology
543:www.denverpost.com
411:Clovisoncology.com
815:on April 14, 2016
745:(23): 7165–7170.
713:on April 13, 2016
343:finance.yahoo.com
188:Boulder, Colorado
163:Boulder, Colorado
148:
147:
116:Boulder, Colorado
894:
866:
865:
855:
831:
825:
824:
822:
820:
811:. Archived from
805:
799:
798:
796:
794:
779:
773:
772:
754:
729:
723:
722:
720:
718:
709:. Archived from
703:
697:
696:
694:
692:
677:
671:
670:
668:
666:
651:
645:
644:
642:
640:
630:
624:
619:
610:
609:
607:
605:
590:
584:
583:
581:
579:
574:on March 5, 2016
570:. Archived from
560:
554:
553:
551:
549:
534:
528:
527:
525:
523:
518:on March 7, 2016
502:
496:
495:
493:
491:
472:
466:
465:
463:
461:
446:
440:
433:
427:
426:
424:
422:
417:on March 9, 2015
403:
397:
396:
394:
392:
378:
372:
371:
369:
367:
353:
347:
346:
335:
329:
328:
326:
324:
309:
133:
132:
91:
89:
84:
31:
24:
902:
901:
897:
896:
895:
893:
892:
891:
872:
871:
870:
869:
846:(11): 2244–51.
833:
832:
828:
818:
816:
807:
806:
802:
792:
790:
781:
780:
776:
731:
730:
726:
716:
714:
705:
704:
700:
690:
688:
679:
678:
674:
664:
662:
653:
652:
648:
638:
636:
632:
631:
627:
620:
613:
603:
601:
592:
591:
587:
577:
575:
568:www.reuters.com
562:
561:
557:
547:
545:
536:
535:
531:
521:
519:
504:
503:
499:
489:
487:
474:
473:
469:
459:
457:
448:
447:
443:
434:
430:
420:
418:
405:
404:
400:
390:
388:
380:
379:
375:
365:
363:
355:
354:
350:
337:
336:
332:
322:
320:
311:
310:
303:
298:
282:VEGFR inhibitor
275:
232:
205:
200:
184:
153:is an American
151:Clovis Oncology
141:
121:
117:
107:Patrick Mahaffy
87:
85:
82:
81:April 2009
60:
50:
22:Clovis Oncology
17:
12:
11:
5:
900:
898:
890:
889:
884:
874:
873:
868:
867:
826:
800:
788:BioPharma Dive
774:
724:
698:
672:
646:
634:"About Clovis"
625:
611:
585:
555:
529:
497:
467:
441:
428:
398:
382:"Overview NBI"
373:
348:
339:"CLVS Profile"
330:
300:
299:
297:
294:
274:
271:
267:chemotherapies
243:ovarian cancer
239:PARP inhibitor
231:
228:
204:
201:
199:
196:
183:
180:
146:
145:
142:
139:
136:
135:
127:
123:
122:
119:
115:
113:
109:
108:
105:
101:
100:
79:
75:
74:
72:Pharmaceutical
69:
65:
64:
51:
46:
43:
42:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
899:
888:
885:
883:
880:
879:
877:
863:
859:
854:
849:
845:
841:
837:
830:
827:
814:
810:
804:
801:
789:
785:
778:
775:
770:
766:
762:
758:
753:
748:
744:
740:
736:
728:
725:
712:
708:
702:
699:
691:September 28,
686:
682:
676:
673:
665:September 28,
660:
656:
650:
647:
635:
629:
626:
623:
618:
616:
612:
599:
595:
589:
586:
573:
569:
565:
559:
556:
544:
540:
533:
530:
517:
513:
512:
507:
501:
498:
485:
481:
477:
471:
468:
456:
452:
445:
442:
438:
432:
429:
416:
412:
408:
402:
399:
387:
383:
377:
374:
362:
358:
352:
349:
344:
340:
334:
331:
318:
314:
308:
306:
302:
295:
293:
291:
287:
283:
279:
272:
270:
268:
264:
260:
256:
255:BRCA mutation
252:
248:
244:
240:
236:
229:
227:
225:
220:
218:
214:
210:
202:
197:
195:
193:
192:Clovis period
189:
181:
179:
177:
172:
168:
164:
160:
156:
152:
143:
137:
128:
124:
114:
110:
106:
102:
99:
95:
80:
76:
73:
70:
66:
63:
59:
55:
52:
49:
44:
41:
38:
34:
30:
25:
19:
843:
839:
829:
817:. Retrieved
813:the original
803:
791:. Retrieved
787:
777:
742:
738:
727:
715:. Retrieved
711:the original
701:
689:. Retrieved
684:
675:
663:. Retrieved
658:
649:
639:November 18,
637:. Retrieved
628:
602:. Retrieved
597:
588:
576:. Retrieved
572:the original
567:
558:
546:. Retrieved
542:
532:
520:. Retrieved
516:the original
511:Fox Business
509:
500:
488:. Retrieved
479:
470:
460:December 12,
458:. Retrieved
454:
444:
431:
419:. Retrieved
415:the original
410:
401:
389:. Retrieved
385:
376:
364:. Retrieved
360:
351:
342:
333:
321:. Retrieved
316:
276:
233:
221:
206:
185:
150:
149:
112:Headquarters
36:Company type
18:
249:granted an
217:osimertinib
209:rociletinib
203:Rociletinib
876:Categories
793:October 4,
604:January 4,
578:January 4,
548:January 4,
421:January 4,
391:January 4,
386:nasdaq.com
366:January 4,
323:January 4,
296:References
761:1557-3265
522:March 15,
455:yahoo.com
437:Form 10-K
278:Lucitanib
273:Lucitanib
235:Rucaparib
230:Rucaparib
48:Traded as
862:25193991
819:April 5,
769:28751443
717:April 5,
490:July 22,
484:Archived
259:germline
159:oncology
98:Colorado
68:Industry
659:Reuters
598:OncLive
263:somatic
261:and/or
182:History
126:Revenue
104:Founder
94:Boulder
88:2009-04
86: (
78:Founded
56::
860:
767:
759:
317:Forbes
167:NASDAQ
54:Nasdaq
40:Public
290:FGFR2
286:FGFR1
280:is a
237:is a
858:PMID
821:2016
795:2023
765:PMID
757:ISSN
719:2016
693:2018
667:2018
641:2016
606:2016
580:2016
550:2016
524:2021
492:2021
462:2022
423:2016
393:2016
368:2016
325:2016
288:and
120:U.S.
58:CLVS
848:doi
747:doi
685:GEN
144:429
92:in
878::
856:.
844:25
842:.
838:.
786:.
763:.
755:.
743:23
741:.
737:.
683:.
657:.
614:^
596:.
566:.
541:.
508:.
478:.
453:.
409:.
384:.
359:.
341:.
315:.
304:^
178:.
118:,
96:,
864:.
850::
823:.
797:.
771:.
749::
721:.
695:.
669:.
643:.
608:.
582:.
552:.
526:.
494:.
464:.
425:.
395:.
370:.
345:.
327:.
257:(
90:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
